Pelvic infection F1: Pelvic infection with PMS, sharp lower abdominal pain, lower back pain, uterine fibroids, miscarriage, infertility or urinary tract stones.
1. Chronic pelvic infection: 79 patients were divided into a treatment group (n=42) taking F1 and a comparison group (n=37) taking regular antibiotics, Vat. C and anti-viral agents. All patients were treated for two months. Cured: 26 vs. 12 (61.90 percent vs. 32.43 percent), significantly improved: 9 vs. 8 (21.42 percent vs. 21.62 percent), improved: 4 vs. 6 (9.52 percent vs. 16.21 percent) and not improved: 3 vs. 11 (7.14 percent vs. 29.72 percent). The treatment group was much better than the comparison group. 58 patients from another report took F1 for two weeks and 93.1 percent improved.
2. PMS: 177 patients in two studies took F1 for three menstrual cycles and 120 were cured (67.79 percent), 12 significantly improved (6.77 percent), 39 improved (22.03 percent) and only 6 did not improve (3.38 percent).
3. Uterine or ovarian fibroids: 115 patients from three studies took F1 from two to five months and 79 were cured (68.69 percent), 4 significantly improved (3.47 percent), 24 improved (20.86 percent) and 8 did not improve (6.95 percent).
4. Frequent miscarriage: 53 patients with frequent miscarriage histories took F1 and 32 were cured successfully delivered a baby -- (60.37 percent) and 21 did not improve (39.62 percent).
5. Female infertility: 140 women from three studies took F1 and 108 became pregnant (77.14 percent). Two reports using F1 with western medicine on 116 patients for up to two months found 74 were pregnant (63.79 percent); the comparison group using only western medicine had 34.4 percent, P<0.05.
6. Urinary tract stones: 100 patients took F1 and 65 were cured with no stones left, 22 significantly improved and 13 did not improve (13 percent).
Side effects and toxicity: Some patients may experience more blood during the first couple of days of menstrual period after taking F1. It's a nomral response after taking F1. If you have any question, please e-mail us. Thanks!
